Rifaximin for better blood thinning after heart attack
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests if adding the gut antibiotic rifaximin to ticagrelor (a blood thinner) can further reduce the risk of blood clots in people who've had a heart attack. It's for patients whose platelets are still too active despite taking ticagrelor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old
- You had a heart attack 1 to 12 months ago
- You take ticagrelor (90 mg twice a day)
- Your blood test shows your platelets are still very active (high reactivity)
- You have not taken antibiotics, probiotics, or steroids in the last 3 months
- You do not have active infections or certain gut diseases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether rifaximin, an antibiotic that works in the gut, can reduce bloating in people with irritable bowel syndrome, constipation, or functional bloating. Rifaximin may help by changing the balance of bacteria in your intestines.
This trial tests if adding the drug Rifaximin can help prevent diarrhea caused by radiation therapy for pelvic cancers. It may be an option for people starting radiation or chemoradiation for non-metastatic pelvic cancer.
This study tests whether taking dabigatran (a blood thinner) combined with ticagrelor (a blood clot preventer) is safe and effective for patients with irregular heart rhythm (atrial fibrillation) who recently had a heart attack and received a stent. The goal is to prevent future blood clots while minimizing bleeding risks.
This trial tests whether the antibiotic rifaximin (taken by mouth) can improve heart function in people with a type of heart failure where the heart pumps well but is still weak (HFpEF). Rifaximin might help by changing the bacteria in your gut.
This trial tests whether an oral antibiotic called rifaximin can improve symptoms during a microscopic colitis flare. It aims to see if it is safe and effective for people whose colitis was confirmed by colon biopsy.
This trial tests if rifaximin, a gut-targeted antibiotic, can help people with fatty liver disease who also have metabolic problems like obesity or diabetes. You need a recent fatty liver diagnosis and a liver fat level of at least 8% on an MRI scan.
Hear when a new Ticagrelor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.